SPL 1.60% 9.6¢ starpharma holdings limited

"Under the terms of the collaboration, Starpharma will license...

  1. 589 Posts.
    lightbulb Created with Sketch. 181
    "Under the terms of the collaboration, Starpharma will license the IP to Petalion on an exclusive basis for a mutually agreed target."

    Rather vague. Is there just one and only one target? Or are there many targets? If there are many targets then exclusivity could scupper most or all of the current potential DEP deals that have been bubbling for years, which could mean that any hope that remains of a megadollar DEP deal in the near future has just flown out of the window.

    "If successful, the oncology therapies that Petalion will develop have the potential to become an important treatment modality for a potentially wide range of cancer indications."

    Note that "therapies" is plural, and note the "wide range".

 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
9.6¢
Change
0.002(1.60%)
Mkt cap ! $39.38M
Open High Low Value Volume
9.4¢ 9.6¢ 9.4¢ $32.09K 339.3K

Buyers (Bids)

No. Vol. Price($)
1 3699 9.5¢
 

Sellers (Offers)

Price($) Vol. No.
9.8¢ 65000 1
View Market Depth
Last trade - 13.54pm 06/08/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.